MedTrace Logo

Radiomics for prEdiction of lunG cAncer biologY

NCT05819905 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-04-19

No results posted yet for this study

Summary

Therapeutic progress for subgroups of Non Small Cell Lung Cancer can largely be attributed to the accumulation of molecular knowledge and the development of new drugs that specifically target molecular abnormalities. An understanding of the immune landscape of tumors, including immune-evasion strategies, has also led to breakthrough therapeutic advances.These new options require prior treatment tumoral sampling to identify patients who have neoplasms with specific genomic aberrations or favorable immune environment. Medical imaging and radiomic approach may provides surrogate markers non invasively.The objective of the present retrospective study is to build and validate a predictive model of common molecular alterations and PD-L1 expression in NSCLC using pre treatment PET/CT derived radiomics.

Conditions

  • Non Small Cell Lung Cancer
  • PET/CT
  • PD-L1
  • Gene Mutation-Related Cancer

Interventions

DIAGNOSTIC_TEST

PET/CT

Pre treatment staging 18F-FDG PET/CT

Sponsors & Collaborators

  • Poitiers University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05819905 on ClinicalTrials.gov